Inogen, Inc.
$6.95
▼
-0.96%
2026-04-21 07:31:01
www.provider.inogen.com
NMS: INGN
Explore Inogen, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$185.18 M
Current Price
$6.95
52W High / Low
$9.13 / $5.34
Stock P/E
—
Book Value
$7.06
Dividend Yield
—
ROCE
-12.85%
ROE
-12.43%
Face Value
—
EPS
$-0.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
753
Beta
1.71
Debt / Equity
9.09
Current Ratio
3.12
Quick Ratio
2.71
Forward P/E
-20.42
Price / Sales
0.49
Enterprise Value
$70.28 M
EV / EBITDA
-7.36
EV / Revenue
0.2
Rating
Strong Buy
Target Price
$12.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SANUWAVE Health, Inc. | $19.94 | 14.99 | $177.13 M | — | 25.36% | -166.66% | $46.59 / $16.27 | $0.19 |
| 2. | Aethlon Medical, Inc. | $2.39 | — | $3.67 M | — | -171.08% | -2.09% | $35.2 / $1.36 | $6.9 |
| 3. | Pacific Biosciences of California, Inc. | $1.74 | — | $510.38 M | — | -78.39% | -2.13% | $2.73 / $0.85 | $0.02 |
| 4. | Pulmonx Corporation | $1.42 | — | $59.98 M | — | -49.13% | -77.19% | $5.46 / $1.13 | $1.3 |
| 5. | Bio-Rad Laboratories, Inc. | NOT FOUND | — | — | — | 2.17% | 10.84% | $343.12 / $211.43 | $276.16 |
| 6. | Koninklijke Philips N.V. | $28.41 | 25.52 | $27.66 B | 0% | 7.46% | 7.82% | $27.7 / $19.09 | $13.43 |
| 7. | Haemonetics Corporation | $61.17 | 16.14 | $2.83 B | — | 10.74% | 19.3% | $87.32 / $47.31 | $19.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 81.72 M | 92.39 M | 92.28 M | 82.28 M | 80.08 M | — |
| Operating Profit | -9.31 M | -7.12 M | -6.13 M | -7.66 M | -11.39 M | — |
| Net Profit | -7.13 M | -5.29 M | -4.15 M | -6.17 M | -9.76 M | — |
| EPS in Rs | -0.26 | -0.19 | -0.15 | -0.23 | -0.36 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 348.67 M | 335.7 M | 315.66 M | 377.24 M |
| Operating Profit | -30.21 M | -42.52 M | -76.49 M | -33.08 M |
| Net Profit | -22.75 M | -35.89 M | -102.45 M | -83.77 M |
| EPS in Rs | -0.84 | -1.32 | -3.76 | -3.08 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 298.62 M | 296.19 M | 326.19 M | 405.04 M |
| Total Liabilities | 106.39 M | 122.33 M | 121.38 M | 107.64 M |
| Equity | 192.23 M | 173.86 M | 204.81 M | 297.41 M |
| Current Assets | 198.3 M | 185.45 M | 207.07 M | 304.64 M |
| Current Liabilities | 63.53 M | 76.69 M | 72.5 M | 65.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -11.22 M | 5.91 M | -3.23 M | -37.53 M |
| Investing CF | -26.21 M | -13.97 M | -59.31 M | -10.88 M |
| Financing CF | 24.18 M | 0.27 M | 0.96 M | 0.38 M |
| Free CF | -21.6 M | -11.18 M | -30.25 M | -58.75 M |
| Capex | -10.38 M | -17.09 M | -27.01 M | -21.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 6.35% | -16.32% | — | — |
| Earnings Growth % | 64.97% | -22.3% | — | — |
| Profit Margin % | -10.69% | -32.46% | -22.21% | — |
| Operating Margin % | -12.66% | -24.23% | -8.77% | — |
| Gross Margin % | 46.09% | 40.14% | 40.7% | — |
| EBITDA Margin % | -6.41% | -18.48% | -2.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.